




**Aptima® HPV**  
Designed With Your Patients and  
Your Practice in Mind



# Maximizing the Benefits

With intervals between recommended screenings for cervical cancer extended, identifying those patients at risk becomes increasingly important. Excellent sensitivity means minimizing false-negative test results. The Aptima® HPV assay, targeting mRNA, has shown equivalent sensitivity to common DNA-based tests:<sup>1-12</sup>




\*Sensitivity for CIN 2+

# While Minimizing Potential Harms

Minimizing false-positives helps clinicians target the right patients for colposcopy. In the NILM arm of the CLEAR trial, Aptima HPV showed 24% fewer false-positive test results compared to hc2.<sup>7</sup>

- Minimizing difficult patient conversations
- Minimizing the potential for over-treatment



\*The graph at left represents data from the Aptima HPV Assay Package Insert Table 13.

Legend: Aptima HPV (purple), hc2 (blue)



# The Aptima® HPV Assay Targeting E6/E7 mRNA:

## The next generation in cervical cancer screening

Aptima® HPV targets high-risk HPV mRNA.

Studies have shown mRNA identifies the presence and activity of a high-risk HPV infection.<sup>13,14</sup>


- Identifying E6/E7 mRNA is indicative of the HPV infections destined to lead to disease.<sup>13,14</sup>

Up to 80% of the population will have an HPV infection at some point in life. Very few will go on to develop cancer.<sup>15</sup>

HPV DNA from one of the 14 high-risk types identifies the presence of a high-risk HPV infection.

- Because HPV DNA levels may decrease as infections progress toward cancer, some HPV DNA tests may provide false-negative results in over 10% of the most severe cervical disease cases.<sup>16</sup>

### mRNA and Cervical Disease



*“The optimal screening strategy should identify those cervical cancer precursors likely to progress to invasive cancers (maximizing the benefits of screening) and avoid the detection and unnecessary treatment of transient HPV infection and its associated benign lesions that are not destined to become cancerous (minimizing the potential harms of screening).”*

— *Am J Clin Pathol* 2012; 137:516-542

# Cervical Cancer Screening Is What We Do

Hologic has been pioneering advances in cervical cancer screening since the FDA approval of the **ThinPrep® Pap test** in 1996.

We were first to introduce computer-aided screening with the FDA approval of the **ThinPrep® imaging system** in 2003.

In 2009, Hologic brought you the first FDA-approved genotyping test: **Cervista® HPV 16/18**.

Today, Hologic brings you the first FDA-approved HPV mRNA test with **Aptima® HPV** and the first genotyping test to include HPV type 45 in the **Aptima HPV 16 18/45 genotype assay**.

ThinPrep Pap test:  
The only liquid-based Pap test with FDA approval/clearance for Pap, HPV, Chlamydia/Gonorrhea and Trichomonas testing from the same vial

## The ThinPrep® Pap Test

**FDA Approved**  
ThinPrep Pap test  
Cervista HPV HR  
Cervista HPV 16/18  
Aptima HPV assay  
Aptima HPV 16 18/45  
Genotype assay  
Roche cobas® HPV test  
Roche cobas AMPLICOR CT/NG  
Digene hc2



**FDA Cleared**  
Aptima Combo 2 assay  
Aptima Trichomonas assay  
BD ProbeTec™ Chlamydia trachomatis (CT)  
BD ProbeTec™ Neisseria gonorrhoeae (GC)

BREAST IMAGING SOLUTIONS • INTERVENTIONAL BREAST SOLUTIONS • BONE HEALTH  
PRENATAL HEALTH • GYNECOLOGIC HEALTH • MOLECULAR DIAGNOSTICS

**At Hologic, we turn passion into action, and action into change.**

Hologic is defining the standard of care in women's health. Our technologies help doctors see better, know sooner, reach further and touch more lives.

## HOLOGIC®

United States / Latin America  
10210 Genetic Center Drive  
San Diego, CA 92121  
Tel: 800.523.5001  
Fax: 800.288.3141  
[hologic.com](http://hologic.com)

**References:** 1. Dockter J, et al. *J Clin Virol*. 2009;45(S1): S55-S61 2. Szarewski A, et al. *Cancer Epidemiol Biomarkers Prev*. 2008; 17(11): 3033-42 3. Szarewski A, et al. *J Clin Micro*. 2012; 50(6): 1867-73 4. Ruschenbach M, et al. *Gynecol Oncol*. 2010; 119(1): 98-105. 5. Clad A, et al. *J Clin Micro*. 2011; 49(3): 1071-76 6. Ratnam S, et al. *J Clin Micro*. 2011; (49(2): 557-64 7. Aptima® HPV Assay package insert #502170 Rev A 2011 8. Wu R, et al. *Int J Gyn Cancer*. 2010; 20(8): 1411-14 9. Monsonog J, et al. *Int J Cancer*. 2011; 129: 691-701 10. Cuzick, J et al. *Br J Cancer*. 2013 March 5; 108(4): 908-913. 11. Iftner, T et al. Comparison of Aptima and HC2 in a routine screening trial in Germany with follow up [abstract]. *International Papillomavirus Conference*; 2012 Nov 30-Dec 6; San Juan, Puerto Rico. 12. Ovestad I, et al. *Gynecol Oncol*. 2011; 123(2): 278-283. 13. Tinelli A, et al. *Curr Pharm Biotechnol*. 2009 Dec;10(8):767-71 14. Cuschieri K, et al. *J Med Virol*. 2004 May;73(1):65-70 15. Centers for Disease Control & Prevention, Rockville MD: CDC National Prevention Information Network; 2009 16. Wright C, et al. *Am J Obstet Gynecol*. 2012 Jan;206(1):46.e1-46.e11

PB-00221-001 Rev. 002 ©2013 Hologic, Inc. All rights reserved. Printed in USA. Specifications are subject to change without prior notice. Hologic, Aptima, ThinPrep and Cervista and associated logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your Hologic representative or write to [womenshealth@hologic.com](mailto:womenshealth@hologic.com).